Literature DB >> 31419737

Attitude and perceptions of patients towards long acting depot injections (LAIs).

Sandeep Grover1, Swapnajeet Sahoo2, Subodh Bn2, Nidhi Malhotra3, Devakshi Dua2, Ajit Avasthi2.   

Abstract

BACKGROUND: Despite the well-established efficacy of the long acting depot injectable (LAIs) antipsychotics, these are significantly underused and underutilized by the mental health professionals, with a belief that patients will not accept the same. AIMS &
OBJECTIVES: To explore the acceptability and perception of patients towards various psychiatric treatments, with specific focus on LAIs. Additionally the study aimed to compare the acceptability of various types of treatments including LAIs between patients with severe mental disorders (Psychotic disorders and Bipolar disorder) and those with Common mental disorders (Anxiety, neurotic and depressive disorders).
METHODOLOGY: A self-designed semi-structured questionnaire was used to evaluate the preferred treatment options of all the new patients attending the psychiatry outpatient clinic of a tertiary care hospital. Depending on the response, they were further probed for the reasons for accepting or rejecting the LAIs.
RESULTS: 2659 patients were interviewed who were divided into two groups (Group I - 321 subjects with psychotic disorders and 120 subjects with bipolar affective disorder (BPAD) and Group II - 2218 subjects with neurotic, stress-related and unipolar depressive disorders). More than three-fourth (78.8%) of the participants in the whole study sample opted for tablets only as their first preferred choice and injectables were opted by about 5% of the participants only, with no significant difference between the 2 groups. After being explained about LAIs, one fourth of the participants (24.9%) reported that they may consider LAIs, without any significant difference between the 2 groups. Among those who refused to take LAIs even after explanation, the commonly reported reasons were difficulty in visiting hospital frequently for the injectables (41.69%), injectables being painful (19.41%), fear of injections (13.96%), no need to take LAIs (12.45%) and preference to take some other types of medicines (8.52%).
CONCLUSIONS: Considering the fact that LAIs are highly underused in patients with severe mental disorders and there is lack of awareness about LAIs among patients with severe mental disorders, the present study findings suggest that there is reasonable level of acceptance of LAIs among patients with severe mental disorders when explained about the same.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Long acting injectables; Treatment acceptance; Treatment preferences

Mesh:

Substances:

Year:  2019        PMID: 31419737     DOI: 10.1016/j.ajp.2019.07.052

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  4 in total

Review 1.  Asenapine Transdermal Patch for the Management of Schizophrenia.

Authors:  Maxine Zhou; Sahar Derakhshanian; Alexander Rath; Sarah Bertrand; Caroline DeGraw; Rachel Barlow; Aja Menard; Adam M Kaye; Jamal Hasoon; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2020-09-14

2.  The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study.

Authors:  Andrea Aguglia; Laura Fusar-Poli; Andrea Amerio; Valeria Placenti; Carmen Concerto; Giovanni Martinotti; Giuseppe Carrà; Francesco Bartoli; Armando D'Agostino; Gianluca Serafini; Mario Amore; Eugenio Aguglia; Giovanni Ostuzzi; Corrado Barbui
Journal:  Front Psychiatry       Date:  2021-12-16       Impact factor: 4.157

3.  Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities.

Authors:  Junli Zhu; Yun Chen; Wei Lu; Qingzhi Huang; Bin Li; Ying Xu; Rui Xi; Lefan Jin
Journal:  Front Public Health       Date:  2021-11-25

4.  Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners.

Authors:  Shaina Schwartz; Christina Carilli; Taimur Mian; Laura Ruekert; Archana Kumar
Journal:  Ment Health Clin       Date:  2022-08-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.